ReviewMedicine2026
Persistent 131I uptake in the thyroglossal duct after thyroid ablation: A case report and literature review.
Review in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
rationalePersistent midline radioiodine uptake after thyroid remnant ablation can mimic metastatic disease and lead to unnecessary re-treatment. We report a case of persistent iodine-131 (131I) uptake in the thyroglossal duct region with undetectable thyroglobulin (Tg). PATIENT CONCERNS: A 45-year-old woman was found to have thyroid nodules on routine ultrasound, and further evaluation supported papillary thyroid carcinoma. DIAGNOSES: After total thyroidectomy and central neck dissection, post-ablation and follow-up 131I imaging demonstrated persistent focal uptake in the midline neck. Single photon emission computed tomography, computed tomography (SPECT/CT) localized the activity to the thyroglossal duct tract, while repeated serum Tg remained undetectable and no structural lesion was identified, supporting a benign thyroglossal duct remnant.
interventionsThe patient underwent total thyroidectomy with central neck dissection, followed by 100 mCi 131I remnant ablation after thyroid hormone withdrawal. She then received levothyroxine for thyroid-stimulating hormone suppression. Six months later, levothyroxine was withdrawn again for 4 weeks, and a low-dose diagnostic 131I scan (3 mCi) with SPECT/CT was performed. OUTCOMES: Diagnostic 131I imaging at 6 months again demonstrated persistent uptake at the same thyroglossal duct site, with no uptake in the thyroid bed, undetectable Tg, and no structural evidence of recurrent disease. The patient was managed conservatively with thyroid-stimulating hormone suppression and periodic biochemical and ultrasound follow-up. LESSONS: For isolated midline 131I uptake after ablation, SPECT/CT localization along the thyroglossal duct tract combined with undetectable Tg supports a benign thyroglossal duct remnant and favors observation with structured follow-up over empiric repeat ablation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.